ABSTRACT

The unprecedented rise in Alzheimer’s disease (AD) with alarming projections of 115 million cases by 2050 worldwide is a serious concern for scientists working in this area. Understanding the involvement of multifactorial components, neuroinflammation coupled with oxidative stress and enhanced acetylcholinesterase activity, in the disease pathogenesis is a step toward alternative drug development therapy. Inadequacy of the currently available treatments to provide a complete cure, as a result of complex events involved in AD, calls for exploration of novel drug delivery agents. Utility of nutraceuticals-based drug delivery for AD has long been realized, but their compromised physicochemical properties (poor solubility, permeability, and unstable nature) prevent their clinical translations. In lieu of this, nanotailored formulations are sought after for their enhanced permeability and targetability across the blood–brain barrier (BBB). This chapter unveils the scope of nanonutraceuticals as potentially vital therapeutics in AD.